Cantitate/Preț
Produs

Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy: Advances in Experimental Medicine and Biology, cartea 1248

Editat de Jie Xu
en Limba Engleză Paperback – 18 mar 2021
This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy.
To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 124945 lei  38-45 zile
  Springer Nature Singapore – 18 mar 2021 124945 lei  38-45 zile
Hardback (1) 126202 lei  38-45 zile
  Springer Nature Singapore – 18 mar 2020 126202 lei  38-45 zile

Din seria Advances in Experimental Medicine and Biology

Preț: 124945 lei

Preț vechi: 131521 lei
-5%

Puncte Express: 1874

Preț estimativ în valută:
23938 25929$ 20528£

Carte tipărită la comandă

Livrare economică 06-13 mai

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9789811532689
ISBN-10: 9811532680
Ilustrații: X, 653 p. 105 illus., 57 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.92 kg
Ediția:1st ed. 2020
Editura: Springer Nature Singapore
Colecția Springer
Seria Advances in Experimental Medicine and Biology

Locul publicării:Singapore, Singapore

Cuprins

Introduction.- Molecular and cellular functions of CTLA-4 pathway.- Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond.- Discovery of new immune checkpoints: family grows up.- Mechanisms of resistance to checkpoint blockade therapy.- Molecular events behind adverse effects.- Rational discovery of response biomarkers.- Spatiotemporal changes in checkpoint molecule expression.- Functions of checkpoint molecules beyond immune evasion.- Genetic alterations and checkpoint expression.- Regulations on messenger RNA: wires and nodes.- Folded or degraded in endoplasmic reticulum.- Mono- and poly-ubiquitination: tags for fates.- Lysosome as the black hole for checkpoint molecules.- Phosphorylation: a fast switch for checkpoint signalling.- Palmitoylation as a signal for delivery.- Checkpoints under traffic control: from and to organelles.- Exosome and secretion: action on?.- Macromolecules and antibody-based drugs.- Mechanisms inspired targeting peptides.- Small molecular inhibitors.- Therapeutic development of immune checkpoint blockers.- Concluding remarks

Notă biografică

Dr. Jie Xu is a Professor at the Institute of Biological Sciences, Fudan University. He is also an associate editor of BMC Cancer, guest associate editor of Frontiers in Pharmacology, and editorial board member of the Journal of Digestive Disease and Gastrointestinal Tumors. Dr. Xu was selected for an Excellent Young Scholar Award by the National Natural Science Foundation of China, Top-Notch Young Talents in China Award by the Chinese Government, and Tang Scholar Award by the Tang International Foundation. Also serving as a review expert for the Changjiang Scholar Program and National Natural Science Foundation of China, his research focuses on mechanisms that control the functions of cytosolic and transmembrane proteins in the contexts of tumor signaling and interactions with immune cells. Dr. Xu has published more than 50 articles in international journals, with relevant patents transferred to major pharmaceutical groups.

Textul de pe ultima copertă

This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy.
To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies.

Caracteristici

Systematically reviewing the most important findings in regulation of cancer immune checkpoints
Discussing the therapeutic development based on molecular and cellular mechanisms
Helping researchers build a roadmap for checkpoint regulation and to develop more effective immunotherapy